Electroacupoint for Diminutive Milk Production
Launched by HAYTHAM IBRAHIM MORSI · Sep 6, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called electroacupoint to help women who are having trouble producing enough breast milk after giving birth by cesarean section. The study is specifically for women aged 25 to 30 who have been breastfeeding but are experiencing low milk supply within the first month after their surgery. To be eligible, participants should be using both breast and bottle feeding and should have a body mass index (BMI) that is not higher than 30, which is a measurement of body weight in relation to height.
Women who join the study can expect to receive this treatment and help researchers understand if it improves milk production. However, there are some health conditions that would prevent someone from participating, such as serious heart or lung issues, diabetes, or previous surgeries in the chest area. This trial is currently recruiting participants, so if you or someone you know is facing these challenges with breastfeeding, this could be a helpful opportunity to explore.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • They were complaining of insufficiency of lactation within the first month after cesarean section.
- • They are using mixed feeding; both breast and bottle feeding, between three and six bottles per day.
- • Their age ranged from 25-30 years old.
- • Their body mass index didn't exceeded 30 kg/m2.
- Exclusion Criteria:
- • Postpartum haemorrhage.
- • Cardiorespiratory disease.
- • Diabetes mellitus.
- • Breast cancer.
- • Previous surgeries in the chest, breast, or the surrounding area.
- • Anemia.
- • Any causes that hindered their normal breastfeeding (retraced, cracked, inflamed, or inverted nipples).
- • Receiving contraceptive pills.
- • Having infants with conditions that may affect the lactation process such as congenital abnormalities of the mouth (tongue tie, cleft palate).
- • Congenital heart disease.
About Haytham Ibrahim Morsi
Haytham Ibrahim Morsi is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Morsi oversees the design and implementation of clinical trials that adhere to the highest ethical and regulatory standards. His extensive experience in the field ensures a robust approach to trial management, fostering collaboration among stakeholders while prioritizing participant safety and data integrity. Through a commitment to scientific excellence, Morsi aims to contribute significantly to the development of new treatments and enhance the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kafrelsheikh, , Egypt
Patients applied
Trial Officials
Haytham I Morsi, M.Sc.
Study Director
Kafrelsheikh University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported